Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.

Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P.

Cancer Biol Ther. 2011 Nov 1;12(9):780-7. doi: 10.4161/cbt.12.9.17781.

PMID:
21892003
2.

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

Chen S, Villeneuve L, Jonker D, Couture F, Laverdière I, Cecchin E, Innocenti F, Toffoli G, Lévesque E, Guillemette C.

Pharmacogenet Genomics. 2015 Dec;25(12):573-83. doi: 10.1097/FPC.0000000000000168.

PMID:
26352872
3.

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.

Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB.

Br J Cancer. 2015 Mar 3;112(5):857-65. doi: 10.1038/bjc.2015.5.

4.

SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer.

Huang L, Zhang T, Xie C, Liao X, Yu Q, Feng J, Ma H, Dai J, Li M, Chen J, Zang A, Wang Q, Ge S, Qin K, Cai J, Yuan X.

PLoS One. 2013 Oct 15;8(10):e77223. doi: 10.1371/journal.pone.0077223.

5.

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.

Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY, Xu JM.

World J Gastroenterol. 2012 Dec 7;18(45):6635-44. doi: 10.3748/wjg.v18.i45.6635.

6.

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL.

Clin Cancer Res. 2005 Feb 1;11(3):1226-36.

7.

[Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].

Sun ZW, Wang XC, Gao J, Li J, Li YY, Dang YZ, Shen L.

Zhonghua Wei Chang Wai Ke Za Zhi. 2013 Jun;16(6):524-8. Chinese.

PMID:
23801203
8.

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.

Lamas MJ, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y, Mosquera A, Giraldez JM, Lopez R, Carracedo A, Barros F.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1591-9. doi: 10.1007/s00280-012-1866-2.

PMID:
22535333
9.

ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan.

Rhodes KE, Zhang W, Yang D, Press OA, Gordon M, Vallböhmer D, Schultheis AM, Lurje G, Ladner RD, Fazzone W, Iqbal S, Lenz HJ.

Drug Metab Lett. 2007 Jan;1(1):23-30.

PMID:
19356014
10.

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS.

Cancer. 2007 Jul 1;110(1):138-47. Erratum in: Cancer. 2010 Aug 1;116(15):3749.

11.

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL.

Clin Cancer Res. 2003 Aug 15;9(9):3246-53.

12.

Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.

Sakaguchi S, Garcia-Bournissen F, Kim R, Schwarz UI, Nathan PC, Ito S.

Arch Dis Child. 2009 Dec;94(12):981-2. doi: 10.1136/adc.2009.163089.

PMID:
19608554
13.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P.

Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3.

PMID:
26607259
14.

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ.

World J Gastroenterol. 2009 Oct 28;15(40):5058-66.

15.

A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes.

Tsunedomi R, Hazama S, Fujita Y, Okayama N, Kanekiyo S, Inoue Y, Yoshino S, Yamasaki T, Suehiro Y, Oba K, Mishima H, Sakamoto J, Hamamoto Y, Oka M.

Int J Oncol. 2014 Oct;45(4):1381-90. doi: 10.3892/ijo.2014.2556.

16.

UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.

Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget M.

Br J Cancer. 2004 Aug 16;91(4):678-82.

17.

Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, Nishina T, Okamura S, Esaki T, Sasaki Y, Koizumi W, Kakeji Y, Ishizuka N, Hyodo I, Sakata Y.

Cancer Sci. 2011 Oct;102(10):1868-73. doi: 10.1111/j.1349-7006.2011.02030.x.

18.

Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.

Zhao J, Li W, Zhu D, Yu Q, Zhang Z, Sun M, Cai S, Zhang W.

Med Oncol. 2014 Jan;31(1):802. doi: 10.1007/s12032-013-0802-6.

19.

Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.

Akiyama Y, Fujita K, Ishida H, Sunakawa Y, Yamashita K, Kawara K, Miwa K, Saji S, Sasaki Y.

Drug Metab Pharmacokinet. 2012;27(3):325-35.

20.

Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).

Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y.

Biol Pharm Bull. 2008 Nov;31(11):2137-42.

Items per page

Supplemental Content

Support Center